Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani,Simeng Lin,Claire Bewshea,Benjamin Hamilton,Amanda Thomas,Rebecca Smith,Christopher Roberts,Maria Bishara,Rachel Nice,Charlie W Lees,Shaji Sebastian,Peter M Irving,Richard K Russell,Timothy J McDonald,James R Goodhand,Tariq Ahmad,Nicholas A Kennedy,PANTS Consortium,Vinod Patel,Zia Mazhar,Rebecca Saich,Ben Colleypriest,Tony C Tham,Tariq Iqbal,Vishal Kaushik,Senthil Murugesan,Salil Singh,Sean Weaver,Cathryn Preston,Assad Butt,Melissa Smith,Dharamveer Basude,Amanda Beale,Sarah Langlands,Natalie Direkze,Miles Parkes,Franco Torrente,Juan De La Revella Negro,Chris Ewen MacDonald,Stephen M Evans,Anton Vj Gunasekera,Alka Thakur,David Elphick,Achuth Shenoy,Chuka U Nwokolo,Anjan Dhar,Andrew T Cole,Anurag Agrawal,Stephen Bridger,Julie Doherty,Sheldon C Cooper,Shanika de Silva,Craig Mowat,Phillip Mayhead,Charlie Lees,Gareth Jones,James W Hart,Yusur Al-Nuaimi,Ellen Richards,Richard Haigh,Huw Greenish,Harry Heath,Daniel R Gaya,Lisa Gervais,Paul Dunckley,Tariq Mahmood,Paul Jr Banim,Sunil Sonwalkar,Deb Ghosh,Rosemary H Phillips,Amer Azaz,Richard Shenderey,Lawrence Armstrong,Claire Bell,Radhakrishnan Hariraj,Helen Matthews,Hasnain Jafferbhoy,Christian P Selinger,Veena Zamvar,John S De Caestecker,Anne Willmott,Richard Miller,Palani Sathish Babu,Christos Tzivinikos,Stuart L Bloom,Guy Chung-Faye,Nicholas M Croft,John Me Fell,Marcus Harbord,Ailsa Hart,Ben Hope,James O Lindsay,Joel E Mawdsley,Alistair McNair,Kevin J Monahan,Charles D Murray,Timothy Orchard,Thankam Paul,Richard Pollok,Neil Shah,Sonia Bouri,Matt W Johnson,Anita Modi,Kasamu Dawa Kabiru,B K Baburajan,Bim Bhaduri,Andrew Adebayo Fagbemi,Scott Levison,Jimmy K Limdi,Gill Watts,Stephen Foley,Arvind Ramadas,George MacFaul,John Mansfield,Leonie Grellier,Mary-Anne Morris,Mark Tremelling,Chris Hawkey,Sian Kirkham,Charles Pj Charlton,Astor Rodrigues,Alison Simmons,Stephen J Lewis,Jonathon Snook,Mark Tighe,Patrick M Goggin,Aminda N De Silva,Simon Lal,Mark S Smith,Simon Panter,Jr Fraser Cummings,Suranga Dharmisari,Martyn Carter,David Watts,Zahid Mahmood,Bruce McLain,Sandip Sen,Anna J Pigott,David Hobday,Emma Wesley,Richard Johnston,Cathryn Edwards,John Beckly,Deven Vani,Subramaniam Ramakrishnan,Rakesh Chaudhary,Nigel J Trudgill,Rachel Cooney,Andy Bell,Neeraj Prasad,John N Gordon,Matthew J Brookes,Andy Li,Stephen Gore
DOI: https://doi.org/10.1016/S2468-1253(24)00044-X
Abstract:Background: We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. Methods: Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab and adalimumab in anti-TNF-naive patients with active luminal Crohn's disease aged 6 years and older. At the end of the first year, sites were invited to enrol participants still receiving study drug into the 2-year PANTS-extension study. We estimated rates of remission across the whole cohort at the end of years 1, 2, and 3 of the study using a modified survival technique with permutation testing. Multivariable regression and survival analyses were used to identify factors associated with loss of response in patients who had initially responded to anti-TNF therapy and with immunogenicity. Loss of response was defined in patients who initially responded to anti-TNF therapy at the end of induction and who subsequently developed symptomatic activity that warranted an escalation of steroid, immunomodulatory, or anti-TNF therapy, resectional surgery, or exit from study due to treatment failure. This study was registered with ClinicalTrials.gov, NCT03088449, and is now complete. Findings: Between March 19, 2014, and Sept 21, 2017, 389 (41%) of 955 patients treated with infliximab and 209 (32%) of 655 treated with adalimumab in the PANTS study entered the PANTS-extension study (median age 32·5 years [IQR 22·1-46·8], 307 [51%] of 598 were female, and 291 [49%] were male). The estimated proportion of patients in remission at the end of years 1, 2, and 3 were, for infliximab 40·2% (95% CI 36·7-43·7), 34·4% (29·9-39·0), and 34·7% (29·8-39·5), and for adalimumab 35·9% (95% CI 31·2-40·5), 32·9% (26·8-39·2), and 28·9% (21·9-36·3), respectively. Optimal drug concentrations at week 14 to predict remission at any later timepoints were 6·1-10·0 mg/L for infliximab and 10·1-12·0 mg/L for adalimumab. After excluding patients who had primary non-response, the estimated proportions of patients who had loss of response by years 1, 2, and 3 were, for infliximab 34·4% (95% CI 30·4-38·2), 54·5% (49·4-59·0), and 60·0% (54·1-65·2), and for adalimumab 32·1% (26·7-37·1), 47·2% (40·2-53·4), and 68·4% (50·9-79·7), respectively. In multivariable analysis, loss of response at year 2 and 3 for patients treated with infliximab and adalimumab was predicted by low anti-TNF drug concentrations at week 14 (infliximab: hazard ratio [HR] for each ten-fold increase in drug concentration 0·45 [95% CI 0·30-0·67], adalimumab: 0·39 [0·22-0·70]). For patients treated with infliximab, loss of response was also associated with female sex (vs male sex; HR 1·47 [95% CI 1·11-1·95]), obesity (vs not obese 1·62 [1·08-2·42]), baseline white cell count (1·06 [1·02-1·11) per 1 × 109 increase in cells per L), and thiopurine dose quartile. Among patients treated with adalimumab, carriage of the HLA-DQA1*05 risk variant was associated with loss of response (HR 1·95 [95% CI 1·17-3·25]). By the end of year 3, the estimated proportion of patients who developed anti-drug antibodies associated with undetectable drug concentrations was 44·0% (95% CI 38·1-49·4) among patients treated with infliximab and 20·3% (13·8-26·2) among those treated with adalimumab. The development of anti-drug antibodies associated with undetectable drug concentrations was significantly associated with treatment without concomitant immunomodulator use for both groups (HR for immunomodulator use: infliximab 0·40 [95% CI 0·31-0·52], adalimumab 0·42 [95% CI 0·24-0·75]), and with carriage of HLA-DQA1*05 risk variant for infliximab (HR for carriage of risk variant: infliximab 1·46 [1·13-1·88]) but not for adalimumab (HR 1·60 [0·92-2·77]). Concomitant use of an immunomodulator before or on the day of starting infliximab was associated with increased time without the development of anti-drug antibodies associated with undetectable drug concentrations compared with use of infliximab alone (HR 2·87 [95% CI 2·20-3·74]) or introduction of an immunomodulator after anti-TNF initiation (1·70 [1·11-2·59]). In years 2 and 3, 16 (4%) of 389 patients treated with infliximab and 11 (5%) of 209 treated with adalimumab had adverse events leading to treatment withdrawal. Nine (2%) patients treated with infliximab and two (1%) of those treated with adalimumab had serious infections in years 2 and 3. Interpretation: Only around a third of patients with active luminal Crohn's disease treated with an anti-TNF drug were in remission at the end of 3 years of treatment. Low drug concentrations at the end of the induction period predict loss of response by year 3 of treatment, suggesting higher drug concentrations during the first year of treatment, particularly during induction, might lead to better long-term outcomes. Anti-drug antibodies associated with undetectable drug concentrations of infliximab, but not adalimumab, can be predicted by carriage of HLA-DQA1*05 and mitigated by concomitant immunomodulator use for both drugs. Funding: Guts UK, Crohn's and Colitis UK, Cure Crohn's Colitis, AbbVie, Merck Sharp and Dohme, Napp Pharmaceuticals, Pfizer, and Celltrion Healthcare.